Quarterly report pursuant to Section 13 or 15(d)

Balance Sheet Components (Tables)

v3.20.2
Balance Sheet Components (Tables)
 9 Months Ended
Sep. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
Components of Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

 

 

 

September 30,

2020

 

 

December 31,

2019

 

Accrued liabilities:

 

 

 

 

 

 

 

 

General and administrative

 

$

1,648

 

 

$

4,521

 

Clinical trial related costs

 

 

2,932

 

 

 

1,383

 

Non-clinical research and manufacturing operations

 

 

4,674

 

 

 

5,774

 

Payroll related

 

 

3,924

 

 

 

2,849

 

Other accrued expenses

 

 

53

 

 

 

17

 

Total Accrued liabilities

 

$

13,231

 

 

$

14,544